Kutane T-Zell-Lymphome: aktueller Stand der Therapie und neue Entwicklungen

Zusammenfassung

Kutane T-Zell-Lymphome (CTCL) stellen eine heterogene Gruppe extranodaler Non-Hodgkin-Lymphome dar. Überwiegend handelt es sich bei ihren Vertretern um chronische, niedrig-maligne Lymphome, die mit einer günstigen Prognose verbunden sind. Andererseits ist auch durch hochaggressive medikamentöse Maßnahmen eine kurative Therapie in der Regel nicht erzielbar. Erkenntnisse zu den Ursachen der einzelnen CTCL-Formen sind nach wie vor spekulativ.

Die verbesserte Klassifikation der CTCL wie auch die Entwicklung neuer Medikamente in den letzten Jahren hat zu differenzierten krankheits- und stadiengerechten Therapieoptionen geführt, die für viele Patienten eine gute Beherrschung ihres Krankheitsbildes möglich macht.

Der Artikel beschreibt den aktuellen Stand der Diagnostik und Therapie der CTCL und gibt einen Ausblick auf innovative in der Entwicklung befindliche Behandlungsansätze.

Abstract

Cutaneous T-cell lymphomas (CTCL) constitute a heterogeneous group of extranodal non-hodgkin lymphomas. Mostly, these entities are chronic low-grade lymphomas showing a favourable prognosis. At the same time even highly aggressive medical treatment will usually not achieve cure. The knowledge on the aetiology of the various CTCL forms is still sparse.

Improvements in classification and the development of new drug during the recent years have led to much differentiated disease and stage specific treatment options, that will provide a good disease control for many patients.

The article describes the current state of diagnosis and treatment of CTCL and gives an overview on innovative and experimental treatment approaches.

• Literatur

• 1 Wong HK, Mishra A, Hake T et al. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011; 155: 150-166
• 2 Hwang ST, Janik JE, Jaffe ES et al. Mycosis fungoides and Sezary syndrome. Lancet 2008; 371: 945-957
• 3 Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785
• 4 Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722
• 5 Edge BD SB, Compton CC, Fritz AG et al. ed. AJCC cancer staging manual. 7.. Aufl. New York: Springer; 2010
• 6 Kaye FJ, Bunn Jr PA, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-1790
• 7 Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther 2003; 16: 288-298
• 8 Deeths MJ, Chapman JT, Dellavalle RP et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5 % cream. J Am Acad Dermatol 2005; 52: 275-280
• 9 Breneman D, Duvic M, Kuzel T et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-332
• 10 Weichenthal M, Schwarz T. Phototherapy: how does UV work?. Photodermatol Photoimmunol Photomed 2005; 21: 260-266
• 11 Stadler R, Assaf C, Klemke CD et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 2008; 6 (Suppl. 01) 25-31
• 12 Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol 2009; 60: 39-50
• 13 Sanchez MA, Gonzalez T, Gaitan MF et al. Is PUVA maintenance therapy necessary in patients with early-stage mycosis fungoides? Evaluation of a treatment guideline over a 28-month follow-up. Int J Dermatol 2011; 50: 1086-1093
• 14 Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284
• 15 Stern RS, Laird N, Melski J et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-1161
• 16 Hofer A, Cerroni L, Kerl H et al. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135: 1377-1380
• 17 Herzinger T, Degitz K, Plewig G et al. Treatment of small plaque parapsoriasis with narrow-band (311 nm) ultraviolet B: a retrospective study. Clin Exp Dermatol 2005; 30: 379-381
• 18 Ahmad K, Rogers S, McNicholas PD et al. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. Acta Derm Venereol 2007; 87: 413-417
• 19 Weber F, Schmuth M, Sepp N et al. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm Venereol 2005; 85: 329-332
• 20 Dereure O, Picot E, Comte C et al. Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results. Dermatology 2009; 218: 1-6
• 21 Edstrom DW, Hedblad MA. Long-term follow-up of photodynamic therapy for mycosis fungoides. Acta Derm Venereol 2008; 88: 288-290
• 22 Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2004; 50: 363-367
• 23 Kontos AP, Kerr HA, Malick F et al. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed 2006; 22: 168-171
• 24 Passeron T, Zakaria W, Ostovari N et al. Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides. Arch Dermatol 2004; 140: 1291-1293
• 25 Navi D, Riaz N, Levin YS et al. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 2011; 147: 561-567
• 26 Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311-321
• 27 Jumbou O, N'Guyen JM, Tessier MH et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999; 140: 427-431
• 28 Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581
• 29 Rupoli S, Barulli S, Guiducci B et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica 1999; 84: 809-813
• 30 Straus DJ, Duvic M, Kuzel T et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007; 109: 1799-1803
• 31 Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471
• 32 Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626-631
• 33 Dummer R, Whittaker S, Hasan B et al. EORTC 21012: Phase II Multicentre Study of Caelyx (TM) Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, IVa and IVb with or without Previous Chemotherapy. Blood 2010; 116: 1164-1165
• 34 Marchi E, Alinari L, Tani M et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-2441
• 35 Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 1870-1877
• 36 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552
• 37 Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491
• 38 Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115
• 39 Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272
• 40 Bernengo MG, Quaglino P, Comessatti A et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-794
• 41 Kim YH, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-4662
• 42 van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138: 191-198
• 43 Booken N, Gratchev A, Utikal J et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 2008; 22: 393-399
• 44 Campbell JJ, Clark RA, Watanabe R et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767-771
• 45 Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-4035
• 46 Duvic M, Donato M, Dabaja B et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 2010; 28: 2365-2372
• 47 Duarte RF, Canals C, Onida F et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4492-4499
• 48 Molina A, Zain J, Arber DA et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163-6171
• 49 Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838-845